Use of stem cells expressing mesenchymal and neuronal markers and compositions thereof to treat neurological disease
Irina Kerkis, São Paulo (BR); and Cristiane Valverde Wenceslau, São Paulo (BR)
Assigned to AVITA INTERNATIONAL LTD., Tortola (VG); and FUNDAÃO BUTANTAN, Sao Paulo (BR)
Filed by AVITA INTERNATIONAL LTD., Tortola (VG); and FUNDAÇÃO BUTANTAN, São Paulo (BR)
Filed on Mar. 21, 2022, as Appl. No. 17/700,458.
Application 17/700,458 is a continuation of application No. 16/125,702, filed on Sep. 8, 2018, granted, now 11,278,574.
Application 16/125,702 is a continuation in part of application No. PCT/IB2017/051404, filed on Mar. 9, 2017.
Application 16/125,702 is a continuation in part of application No. 15/065,259, filed on Mar. 9, 2016, granted, now 11,207,352, issued on Dec. 28, 2021.
Application PCT/IB2017/051404 is a continuation in part of application No. 14/214,016, filed on Mar. 14, 2014, granted, now 9,790,468, issued on Oct. 17, 2017.
Claims priority of provisional application 61/791,594, filed on Mar. 15, 2013.
Claims priority of provisional application 61/800,245, filed on Mar. 15, 2013.
Claims priority of provisional application 62/130,593, filed on Mar. 9, 2015.
Claims priority of provisional application 62/130,585, filed on Mar. 9, 2015.
Claims priority of provisional application 62/220,792, filed on Sep. 18, 2015.
Prior Publication US 2022/0211765 A1, Jul. 7, 2022
1. A method of treating a neurodegenerative condition, comprising systemically administering to a subject a pharmaceutical composition comprising hIDPSCs, wherein the hIDPSCs express CD44 and CD13.